CO-OPTIV-SECURITY
23.9.2019 10:07:05 CEST | Business Wire | Press release
With the rise of the data breach epidemic, and the imposition of comprehensive privacy regulations and significant legislation requirements, cybersecurity has become a tier-one business risk. As a result, the chief information security officer’s (CISO) role in a business has dramatically increased in value. In fact, 64 percent of businesses now prioritise cybersecurity above all else, even if it slows some users’ productivity down, according to a new research report from Optiv Security . The report, “The State of the CISO,” takes an in-depth look at the approach to cybersecurity taken by CISOs, CSOs and senior IT decision makers, the strategies they have in place and their experience of data breaches.
Cybersecurity becomes a business priority
The research found that the importance of cybersecurity is now better understood by business executives and board members. In fact, 96 percent of respondents indicated they are taking a more strategic approach to cybersecurity as a result of being greater aligned with business leaders.
“Some organisations are further along this evolutionary curve than others, but without business’ buy-in to a cybersecurity program, CISOs will undoubtedly struggle to keep their organisations safe from looming cyber threats,” said Andrzej Kawalec, Optiv’s director of strategy and technology, Europe. “We are seeing a significant shift in the industry, whereby cybersecurity is now a business issue. CISOs are being regarded as an important part of major business initiatives such as next-generation digital transformation, which has led to more funding for cyber programs. The board now understands that a major security or compliance miscue can derail a business.”
When it comes to the approach to cybersecurity, the research found that 66 percent of IT security decision makers felt greater awareness of security risks within the IT function has had a significant impact on currently existing cybersecurity policies. Compliance with external standards such as GDPR follows closely behind at 56 percent, but basic functions like vulnerability and patching is only prioritised by 32 percent of respondents. Employee education was deemed a top priority by 58 percent of respondents, as was simplifying infrastructure (54 percent) and aligning security with development operations to create a DevSecOps model (47 percent).
“It is concerning in light of the fact that, by some estimates, unpatched vulnerabilities account for more than half of all data breaches,” continued Kawalec. “By getting the basic functions of cybersecurity right, IT decision makers can drastically improve their chances of defending against a cyber-attack, since unpatched software is often cited as the most common cause of data breaches.”
The greatest security threats
The research also identified that 31 percent of respondents believe that organized crime and politically motivated acts are seen as the greatest threats to cybersecurity, while 28 percent believe this to be hacktivists. Insider threats are seen as critical by 26 percent and just 15 percent of respondents cited third parties as a threat to their cybersecurity. To deal with cybersecurity threats, 92 percent of respondents have an incident response plan in place, but rehearsing this plan is lagging, with 44 percent of businesses stating they only rehearse once a year or less.
The report finds that breaches still seem to serve as a wake-up call for organizations, with 39 percent of businesses implementing changes in their security program only after an incident. While 65 percent cited that recovery from the breach was well coordinated and successful, over a third (35 percent) reported that recovery costs were still higher than it would have cost to invest in better breach defence.
To read the full report, please visit Optiv’s website .
Methodology
Optiv launched an independent research series to discover how IT decision makers approach cybersecurity. To produce its research and resulting report, Optiv worked with London-based research agency, Loudhouse. Loudhouse is an independent agency that specializes in technology and B2B research for global brands.
Loudhouse conducted online interviews with 100 US- and 100 UK-based CISOs, CSOs and Senior IT decision makers at enterprise businesses (between 500 and 5000+ employees), to understand their approach to cybersecurity, the strategies they have in place, and their experience of data breaches.
Follow Optiv
Twitter: www.twitter.com/optiv
LinkedIn: www.linkedin.com/company/optiv-inc
Facebook: www.facebook.com/optivinc
YouTube: https://www.youtube.com/c/OptivInc
Blog: https://www.optiv.com/explore-optiv-insights/blog
Optiv Security: Who Secures Your Insecurity?
™
Optiv is a security solutions integrator – a global, “one-stop” trusted partner with a singular focus on cybersecurity. Our end-to-end cybersecurity capabilities span risk management and transformation, cyber digital transformation, threat management, cyber operations, identity and data management, and integration and innovation, helping organisations realize stronger, simpler and more cost-efficient cybersecurity programs that support business requirements and outcomes. At Optiv, we are modernizing cybersecurity to enable clients to innovate their consumption models, integrate infrastructure and technology to maximize value, achieve measurable outcomes, and realize complete solutions and business alignment. For more information about Optiv, please visit us at www.optiv.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190923005132/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
